ADCs are a targeted approach to the treatment of cancer, and as ever more of these complex products enter clinical development, the need to scale up production of their payloads becomes a pressing topic. In this webinar, participants will hear about Lonza’s investment in facilities capable of producing large quantities (100+ kg) under the strictest levels of containment.

Watch now to learn more about:

  • Key market trends
  • Lonza’s approach to lifecycle investment
  • Leadership in HPAPI facility & process design

Who should watch on-demand:

  • Key clients / potential clients from the ADC arena, covering all disciplines from biologics/ bioconjugation and payload-linker




You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center